Fangzhou Inc. Recognized for AI Innovation in Healthcare, Secures Top Honors and National High-Tech Enterprise Status

Fangzhou named most promising as its smart health platform gets top honors

Fangzhou Inc. has clinched a dual honor as its H2H Smart Healthcare Ecosystem becomes one of Guangzhou's Top 10 AI+Healthcare Cases, while the company itself lands the title of "Most Promising Enterprise" on the city's 2024 Artificial Intelligence Innovation Development List. The awards, issued by Guangzhou's science and technology authorities, highlight its AI-powered healthcare innovations. "This validates our success in creating scalable, real-world AI solutions for healthcare," said Dr. Xie Fangmin, founder and CEO of Fangzhou. "Our focus remains on building smarter systems that make healthcare more efficient and accessible for everyone." Fangzhou fused Tencent Health's DeepSeek-V3 and DeepSeek-R1 AI models into its upgraded AI Agent 2.0 platform, using Tencent Cloud's infrastructure to boost drug logistics and patient care efficiency. Four tools -- AI Physician Assistant, AI Customer Engagement Assistant, AI Procurement Orchestrator, and AI Content Assistant -- power the H2H platform, streamlining diagnostics to supply chain operations while enhancing customer experiences. Fangzhou's chronic disease management platform connects 49.2 million users and 223,000 physicians, delivering personalized care and precision medicine services as of December 2024. Now in its third year, the initiative spotlights top AI-driven enterprises while boosting collaboration to fuel Guangzhou's expanding tech ecosystem.

Fangzhou Designated as a 2024 National High-Tech Enterprise Amid Record Growth By Investing.com

BEIJING, April 3, 2025 /PRNewswire/ -- Beijing Fangyixing Information Technology Co., Ltd. ("Fangyixing"), a subsidiary of China's leading Internet healthcare solutions provider Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), has been certified as a 2024 National High-Tech Enterprise, solidifying its role as a pioneer in AI-powered healthcare innovation. The designation, jointly awarded by the Beijing Science and Technology Commission, Beijing Finance Bureau and Beijing Municipal Tax Service, recognizes Fangyixing's strengths in core intellectual property, commercialization of scientific achievements, and robust R&D management. Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, commented, "This honor validates our long-term commitment to R&D and empowers us to further scale AI innovations within our H2H Smart Healthcare Ecosystem. We will continue to deepen collaborations with industry leaders and accelerate the translation of cutting-edge research into accessible and life-changing healthcare solutions." Strong Financial Performance Driven by Robust Innovation Fangzhou's inaugural post-IPO annual results highlighted its dual trajectory of growth and innovation: 2024 revenue grew 11.2% YoY to RMB2.707 billion, while adjusted net profit increased by 139% YoY to RMB17.1 million. This significant growth reflects Fangzhou's sustained investment in and focus on AI-enabled technologies as a core driver of business value and operating efficiency. AI-Driven Growth and Strategic Vision Fangzhou's growth objectives are aligned with its deployment of AI models such as DeepSeek-V3 and partnerships with Tencent Health and Tencent Cloud to accelerate AI-driven healthcare solutions. Fangzhou will further strengthen its technological capabilities and accelerate the commercialization of innovations, with a goal of delivering improved user experiences for patients and customers. About Fangzhou Inc. Fangzhou Inc. (06086.HK) is China's leading online chronic disease management platform, serving 49.2 million registered users and 223,000 physicians (as of December 31, 2024). The Company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit https://investors.jianke.com. About the "National High-Tech Enterprise" The National High-Tech Enterprise designation represents China's most prestigious recognition for technological excellence, awarded to companies that demonstrate cutting-edge innovation in priority sectors. Qualifying enterprises must demonstrate sustained R&D investment, successful commercialization of proprietary technologies, and domestic or international leadership in converting advanced research into productive applications. This certification serves as the gold standard for validating a company's scientific capabilities and innovation-driven business model in China's competitive tech landscape. Media Contact For further inquiries or interviews, please reach out to: Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com

Fangzhou Inc. Named Among Guangzhou's Top AI Innovators for Intelligent Healthcare Platform By Investing.com

GUANGZHOU, China, March 27, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, has been named to the 2024 Guangzhou Artificial Intelligence Innovation Development List as "Most Promising Enterprise," while its H2H Smart Healthcare Ecosystem secured a spot on the "Application Scenario Innovation List" as a Top 10 AI+Healthcare Case. The awards, issued by the Guangzhou Municipal Science and Technology Bureau, highlight Fangzhou's groundbreaking innovations in technology and its leadership in transforming the digital healthcare industry. Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, commented, "Being recognized among Guangzhou's top AI innovators reflects Fangzhou's success in developing practical and scalable AI solutions for healthcare. This achievement reinforces our commitment to advancing an intelligent healthcare ecosystem that improves efficiency and accessibility." Strategic AI Collaboration with Tencent Fangzhou has deepened its collaboration with Tencent Health and Tencent Cloud to accelerate AI-driven healthcare solutions, integrating the open-source DeepSeek-V3 and DeepSeek-R1 models into its platform. Following the local deployment of DeepSeek's large language model in February, the partnership leverages Tencent's cloud infrastructure to power Fangzhou's upgraded "AI Agent 2.0" platform, targeting transformative applications in pharmaceutical logistics and healthcare services. Flagship AI Modules for Enhanced Efficiency The Company's "AI + H2H Smart Healthcare Ecosystem" features four core AI modules: AI Physician Assistant, AI Customer Engagement Assistant, AI Procurement Orchestrator, and AI Content Assistant. These tools are designed to streamline operations " from diagnostics to supply chain management " while improving patient and customer experiences across the platform. About Fangzhou Inc. Fangzhou Inc. (06086.HK) is China's leading online chronic disease management platform, serving 49.2 million registered users and 223,000 physicians (as of December 31, 2024). The Company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit https://investors.jianke.com. About the "Guangzhou Artificial Intelligence Innovation Development List" Now in its third consecutive year, the "Guangzhou AI Innovation Development List" recognizes the city's most impactful and promising artificial intelligence enterprises. By highlighting these industry leaders and their cutting-edge applications, the initiative strengthens collaboration across Guangzhou's AI value chain and fosters a more connected ecosystem. Media Contact For further inquiries or interviews, please reach out to: Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com